Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine
| Author | Arash Mahboubi | en |
| Author | Mohammad Reza Fazeli | en |
| Author | Nasrin Samadi | en |
| Author | Rasoul Dinarvand | en |
| Author | Saeed Azadi | en |
| Issued Date | 2012-01-31 | en |
| Abstract | Thimerosal, which is approximately 50% mercury by weight is a preservative widely used in vaccines since the 1930’s. It meets the requirements for a preservative as set forth by Pharmacopeia challenge test and has been shown to be effective against a broad spectrum of pathogens. In July 1999, the Public Health Service agencies and vaccine manufacturers agreed that thimerosal should be reduced or eliminated in vaccines as a precautionary measure but, due to the lack of appropriate alternative, it is still extensively used in multiple dose formulations of vaccines such as hepatitis-B in developing countries. In this study the effect of the removal of thimerosal in two formulations of hepatitis B vaccines containing either aluminum hydroxide or aluminum phosphate were evaluated in Balb/c mice. These formulations were administered interperitoneally and the titer of antibody was determined by ELISA technique after 28 days. | en |
| DOI | https://doi.org/10.22037/ijpr.2012.1061 | en |
| Keyword | Hepatitis B vaccine | en |
| Keyword | Thimerosal | en |
| Keyword | Aluminum salts | en |
| Keyword | GMT | en |
| Keyword | Relative potency | en |
| Publisher | Brieflands | en |
| Title | Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine | en |
| Type | Case Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- IJPR-011-039.pdf
- Size:
- 537.82 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF